Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over the past three months. Since the market usually pay for a company’s long-term ...

A clear picture of TG Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent ...

Breaking Down Analyst Ratings: A Detailed Examination A clear picture of TG Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions.

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX) has released updated data from its ENHANCE Phase 3b trial concerning BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX) has released updated data from its ENHANCE Phase 3b trial concerning BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple ...

H.C. Wainwright has reaffirmed its Buy rating and $49.00 price target for shares of TG Therapeutics (NASDAQ: NASDAQ:TGTX). The firm's endorsement follows the recent presentation of new data from ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...